The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer

Sarah Sharman Moser1 Maccabi Institute for Research and Innovation (Maccabitech)Maccabi Healthcare Services27 Hamered St6812509Tel AvivIsraelCorrespondence[email protected]

https://orcid.org/0000-0002-9745-2016

Frank Tanser2 Lincoln International Institute of Rural Health, Lincoln Medical SchoolUniversity of LincolnBrayford Way, Brayford PoolLN6 7TSLincolnUK

Nava Siegelmann-Danieli1 Maccabi Institute for Research and Innovation (Maccabitech)Maccabi Healthcare Services27 Hamered St6812509Tel AvivIsrael;3 Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael

Lior Apter1 Maccabi Institute for Research and Innovation (Maccabitech)Maccabi Healthcare Services27 Hamered St6812509Tel AvivIsrael;4 Department of Health Systems ManagementBen-Gurion University of the NegevBeer-ShevaIsrael

Gabriel Chodick1 Maccabi Institute for Research and Innovation (Maccabitech)Maccabi Healthcare Services27 Hamered St6812509Tel AvivIsrael;3 Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael

Josie Solomon5 The School of Pharmacy, Joseph Banks LaboratoriesUniversity of LincolnBeevor StreetLN6 7DLLincolnUK

The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date